Janux Therapeutics (NASDAQ:JANX) Earns Outperform Rating from William Blair

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a research note issued to investors on Tuesday,RTT News reports.

Several other analysts have also recently weighed in on JANX. HC Wainwright boosted their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. Leerink Partners began coverage on Janux Therapeutics in a research note on Friday, November 22nd. They issued an “outperform” rating and a $79.00 price target for the company. Stifel Nicolaus began coverage on Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price target for the company. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $79.90.

Janux Therapeutics Stock Up 11.7 %

Shares of NASDAQ JANX opened at $66.84 on Tuesday. The firm’s 50-day simple moving average is $49.83 and its 200 day simple moving average is $45.81. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -57.12 and a beta of 3.29. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $71.25.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. On average, equities analysts expect that Janux Therapeutics will post -1.35 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 14.78 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the transaction, the chief executive officer now directly owns 242,054 shares of the company’s stock, valued at approximately $16,217,618. This trade represents a 5.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 460,610 shares of company stock valued at $21,583,666. 29.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of large investors have recently bought and sold shares of the company. Franklin Resources Inc. boosted its holdings in shares of Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Janux Therapeutics in the 3rd quarter valued at approximately $940,000. Geode Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.